CA9, which is not expressed in most benign tissues, is abundant in many cancers including renal cancer, bladder cancer, oral cancer, lung cancer and uterine cancer and has been thought to be an endogenous marker for tumor hypoxia [13–20]. Here, CA9 is linked to urinary bladder cancer.